Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
10.3389/fphar.2025.1562896 73 Svegliati-BaroniG.SaccomannoS.RychlickiC.AgostinelliL.De MinicisS.CandelaresiC.et al (2011)
These breakthroughs will continue to improve health outcomes for people with obesity, helping them achieve meaningful, long-term weight loss and better overall health
This combination can produce synergistic effects but also increases complexity and risk
STEP-HFpEF Trial Committees and Investigators, Kosiborod MN, Abildstrm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity
Description Product Overview RETA (Retatrutide) is an investigational research peptide studied in laboratory and pre-clinical environments for its interaction with multiple metabolic and energy-regulating hormone receptor pathways
At 72 weeks, tirzepatide vs semaglutide produced 20.2% mean weight loss versus 13.7% in SURMOUNT-5, the first randomized head-to-head trial between them (NEJM, May 2025)
/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2023/3/i/e2AW7wSDiGOE5HAOzWkw/tirzepatida-20mounjaro.jpg)
US$ 27.83
US$ 29.03
US$ 21.50
US$ 26.98
US$ 25.62
US$ 21.67
US$ 20.55
US$ 24.46
US$ 25.72
